Insilico Medicine Cayman TopCo reported a sharp turnaround for the six months ended 30 June 2026, delivering a net profit of USD35.54 million versus a USD19.22 million loss a year earlier.

Revenue surged 287.2 % to USD106.30 million, driven mainly by drug-discovery and pipeline-development income, which jumped 331.3 % to USD103.13 million and accounted for 97 % of total sales. Software-solution revenue grew to USD2.70 million, while income from other discovery services reached USD0.48 million. Gross profit climbed to USD95.97 million, lifting the gross margin to 90.3 % from 83.8 %.

Operating costs rose alongside expansion: research and development spending increased 38.7 % year on year to USD49.33 million, selling and marketing expenses more than doubled to USD6.37 million, and administrative costs rose 79.5 % to USD12.58 million. Share-based compensation expenses totalled USD15.69 million, underpinning an adjusted profit of USD51.23 million.

Cash resources remained robust. Bank balances, cash and term deposits totalled USD466.57 million at period-end. Net assets expanded to USD547.06 million from USD452.03 million at end-2025, aided by USD41.61 million raised through the full exercise of the IPO over-allotment option in January 2026. The company also drew USD17.49 million in new short-term borrowings and invested about USD122.01 million in money-market and other financial products.

Operationally, Insilico accelerated its pipeline to 33 pre-clinical candidates, initiated a Phase III China trial for lead anti-fibrotic Rentosertib (ISM001-055), and nominated nine additional pre-clinical candidates during the half-year. Business-development momentum remained strong: year-to-date contracted deal value from out-licensing and research collaborations totalled approximately USD7.30 billion, including a landmark agreement with Eli Lilly worth up to USD2.75 billion.

No interim dividend was declared.